NEW YORK (GenomeWeb News) – Maven Biotechnologies is seeking a buyer for its label-free detection and imaging technology.

The technology called LFIRE is a method for detection and ellipsometry reflection and provides enhanced, high-content, label-free detection and imaging and high-capacity screening. Today, BioMed Transition Partners announced Maven Bio has retained its services to help find a buyer for the technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.